Get the Stockscreener App
27.07
0.11%
-0.03
Edgewise Therapeutics Inc stock is traded at $27.07, with a volume of 1.03M.
It is down -0.11% in the last 24 hours and down -1.17% over the past month.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
See More
Previous Close:
$27.10
Open:
$27.39
24h Volume:
1.03M
Relative Volume:
1.19
Market Cap:
$2.56B
Revenue:
-
Net Income/Loss:
$-115.88M
P/E Ratio:
-17.50
EPS:
-1.5468
Net Cash Flow:
$-104.72M
1W Performance:
+6.62%
1M Performance:
-1.17%
6M Performance:
+29.27%
1Y Performance:
+54.69%
1-Day Range:
$26.62
$29.00
1-Week Range:
$25.17
$29.14
52-Week Range:
$14.90
$38.12
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Name
Edgewise Therapeutics Inc
Sector
Industry
Phone
720-262-7002
Address
1715 38TH ST, BOULDER
Compare EWTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
27.07 | 2.56B | 0 | -115.88M | -104.72M | -1.5468 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-25 | Initiated | Stifel | Hold |
| Nov-22-24 | Initiated | Evercore ISI | Outperform |
| Mar-07-24 | Initiated | Piper Sandler | Overweight |
| May-01-23 | Initiated | Truist | Buy |
| Aug-25-22 | Downgrade | Goldman | Neutral → Sell |
| Apr-13-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-28-22 | Initiated | Goldman | Neutral |
View All
Edgewise Therapeutics Inc Stock (EWTX) Latest News
Edgewise Therapeutics (EWTX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Shares Up 5.9%Here's Why - MarketBeat
10,316 Shares in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Acquired by AlphaCentric Advisors LLC - MarketBeat
Should You Invest in Edgewise Therapeutics (EWTX)? - Insider Monkey
What is Edgewise Therapeutics Inc (EWTX) Stock Return on Shareholders’ Capital? - SETE News
Strong Buy Stocks: Udemy, D-Wave Quantum, and Edgewise Therapeutics - PUNE.NEWS
How To Trade (EWTX) - Stock Traders Daily
JPMorgan lifts Edgewise Therapeutics target to $45 - MSN
JPMorgan lifts Edgewise Therapeutics target to $45 By Investing.com - Investing.com UK
Edgewise placed on ‘Positive Catalyst Watch’ at JPMorgan - TipRanks
abrdn plc Sells 78,602 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Insider Alan J. Russell Sells 1,200 Shares - MarketBeat
Insider Selling: Edgewise Therapeutics, Inc. (NASDAQ:EWTX) CEO Sells 8,636 Shares of Stock - MarketBeat
Edgewise Therapeutics chief business officer sells $300,300 in stock - MSN
Edgewise Therapeutics (NASDAQ:EWTX) Shares Down 7.1% Following Insider Selling - MarketBeat
April 17th Options Now Available For Edgewise Therapeutics (EWTX) - Nasdaq
What was Edgewise Therapeutics Inc (EWTX)’s performance in the last session? - US Post News
Edgewise Therapeutics chief scientific officer sells $276,776 in stock - MSN
Edgewise Therapeutics CEO Kevin Koch sells $287,315 in stock - MSN
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Edgewise Therapeutics' SWOT analysis: novel therapies drive stock potential - MSN
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) CEO Kevin Koch Sells 8,636 Shares of Stock - Armenian Reporter
Edgewise Therapeutics CEO Kevin Koch sells $287,315 in stock By Investing.com - Investing.com Australia
Edgewise Therapeutics chief business officer sells $300,300 in stock By Investing.com - Investing.com South Africa
Edgewise Therapeutics chief scientific officer sells $276,776 in stock By Investing.com - Investing.com Nigeria
Edgewise Therapeutics Executives Sell Shares - TradingView
An In-Depth Look at Edgewise Therapeutics Inc’s (EWTX) Stock Performance - The News Heater
Can you now get a good deal on Edgewise Therapeutics Inc’s shares? - US Post News
When (EWTX) Moves Investors should Listen - Stock Traders Daily
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap UpStill a Buy? - MarketBeat
Ratios Uncovered: Breaking Down Edgewise Therapeutics Inc (EWTX)’s Trailing Twelve Months Metrics - The Dwinnex
Check out these key findings about Edgewise Therapeutics Inc (EWTX) - SETE News
Edgewise Therapeutics' SWOT analysis: novel therapies drive stock potential By Investing.com - Investing.com South Africa
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) CMO Joanne M. Donovan Sells 25,000 Shares - MarketBeat
Edgewise Therapeutics Inc Stock (EWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Edgewise Therapeutics Inc Stock (EWTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Russell Alan J | Chief Scientific Officer |
Feb 06 '25 |
Option Exercise |
0.18 |
1,200 |
216 |
16,063 |
| Russell Alan J | Chief Scientific Officer |
Feb 05 '25 |
Sale |
30.02 |
8,015 |
240,623 |
14,863 |
| Russell Alan J | Chief Scientific Officer |
Feb 06 '25 |
Sale |
30.13 |
1,200 |
36,153 |
14,863 |
| KOCH KEVIN | President and CEO |
Feb 06 '25 |
Option Exercise |
13.11 |
900 |
11,799 |
15,378 |
| KOCH KEVIN | President and CEO |
Feb 05 '25 |
Option Exercise |
0.18 |
8,636 |
1,554 |
23,114 |
| KOCH KEVIN | President and CEO |
Feb 05 '25 |
Sale |
30.03 |
8,636 |
259,298 |
14,478 |
| KOCH KEVIN | President and CEO |
Feb 06 '25 |
Sale |
31.13 |
900 |
28,018 |
14,478 |
| Derakhshan Behrad | Chief Business Officer |
Feb 05 '25 |
Option Exercise |
1.93 |
10,000 |
19,300 |
26,837 |
| Derakhshan Behrad | Chief Business Officer |
Feb 05 '25 |
Sale |
30.03 |
10,000 |
300,300 |
16,837 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):